Kenneth Goldman and Briskin Family Clinical Trials Program
A key part of City of Hope's mission is our determination to leverage world-class research into leading-edge therapies and make them available to patients as rapidly as possible. Clinical trials play a vital role in this work. The Kenneth Goldman and Briskin Family Clinical Trials Program manages and coordinates all trials related to the treatment of multiple myeloma, as part of the Judy and Bernard Briskin Center for Multiple Myeloma Research. Our clinical trial portfolio is constantly changing as we seek the best agents. These include drugs targeting high-risk myeloma, bispecific antibodies and immune checkpoint inhibitors.
Multiple Myeloma Clinical Trials
Bispecific Antibodies
NCT03145181: IRB#17138 — A Phase 1, first-in-human, open-label, dose escalation study of of JNJ 64007957, a humanized BCMA x CD3 DuoBody in subjects with relapsed or refractory multiple myeloma (MMY1001) [teclistamab]
Patient Enrollment Qualifications
- Women and men 18 years of age or older
- Diagnosed with multiple myeloma
___________________
NCT03399799: IRB #17434 — Protocol 64407564MMY1001: A Phase 1, first-in-human, open-label, dose escalation study of JNJ-64407564, a humanized GPRC5D x CD3 DuoBody® antibody, in subjects with relapsed or refractory multiple myeloma (talquetamab)
Patient Enrollment Qualifications
- Women and men 18 years of age or older
- Diagnosed with multiple myeloma
_______________________
NCT05083169: IRB #21704 — Protocol 64007957MMY3001: A Phase 3 randomized study comparing teclistamab in combination with daratumumab SC (Tec-Dara) versus daratumumab SC, pomalidomide, and dexamethasone (DPd) or daratumumab SC, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (MajesTEC-3)
Patient Enrollment Qualifications
- Women and men 18 years of age or older
- Diagnosed with multiple myeloma
_______________________
NCT03275103: IRB #17209— An open-label, multicenter, Phase I trial evaluating the safety and pharmacokinetics of escalating doses of BFCR4350A (Cevostamab) in patients with relapsed or refractory multiple myeloma (Genentech GO39775)
Patient Enrollment Qualifications
- Women and men 18 years of age or older
- Life expectancy must exceed 12 weeks
CAR T Cells or CAR NK Cells
NCT03710421: IRB #17403 — A Phase I study to evaluate cellular immunotherapy using memory-enriched T cells lentivira (CS1)
Patient Enrollment Qualifications
- Women and men 18 years of age or older
-
Diagnosed with multiple myeloma
_______________________
NCT04674813: IRB #20596 — A Phase 1, multicenter, open-label study of CC-95266 (GPRC5D CAR T) in subjects with relapsed or refractory multiple myeloma
Patient Enrollment Qualifications
- Women and men 18 years of age or older
- Diagnosed with multiple myeloma with relapsed or refractory disease
_______________________
NCT05182073: IRB #22027 — A Phase I study of FT576 as monotherapy and in combination with daratumumab in subjects with relapsed or refractory multiple myeloma
Patient Enrollment Qualifications
- Women and men 18 years of age or older
- Diagnosed with relapsed/refractory multiple myeloma with measurable disease by at least one of the following:
- Serum M-protein ≥1.0 g/dL
- Urine M-protein ≥200 mg/24 hours
Radioimmunotherapy
NCT05353111: IRB #21599 — A Phase 1 Trial of 225Actinium-DOTA-daratumumab in patients with relapsed or refractory multiple myeloma
Patient Enrollment Qualifications
- Women and men 18 years of age or older
- Diagnosed with multiple myeloma
Drug Repurposing
NCT04508790: IRB #19418 — A Phase 2 Trial of leflunomide, pomalidomide, and dexamethasone for relapsed or refractory multiple myeloma
Patient Enrollment Qualifications
- Women and men 18 years of age or older
- Life expectancy must exceed three months
_______________________
NCT05014646: IRB #21049 — Phase 2 trial of leflunomide in African American and European American patients with high-risk smoldering multiple myeloma
Patient Enrollment Qualifications
- Women and men 18 years of age or older
-
Life expectancy must exceed two years
Immunomodulatory Drugs
NCT03374085: IRB #17365 — A Phase 1/2 study of CC-92480 in relapsed or refractory multiple myeloma (Celgene CC-92480-MM-001)
Patient Enrollment Qualifications
- Women and men 18 years of age or older
- Diagnosed with multiple myeloma
Maintenance Approaches
NCT03346135: IRB #18560 — A multicenter, open-label, single arm, Phase II study of daratumumab as consolidation/maintenance therapy after autologous stem cell transplantation in patients with multiple myeloma
Patient Enrollment Qualifications
- Women and men 18 to 70 years of age
- Diagnosed with multiple myeloma — patients with multiple myeloma and secondary amyloidosis are eligible
_______________________
NCT04071457: IRB #19310 — A Phase III Study of daratumumab/rHuPH20 (NSC-810307) + lenalidomide or lenalidomide as post-autologous stem cell transplant maintenance therapy in patients with multiple myeloma (MM) using minimal residual disease to direct therapy duration (DRAMMATIC study)
Patient Enrollment Qualifications
- Women and men 18 to 75 years of age
- Diagnosed with symptomatic multiple myeloma
Amyloidosis
NCT04847453: IRB #21395 — A Phase 1/1a study of venetoclax, MLN9708 (ixazomib citrate) and dexamethasone for relapsed or refractory light chain amyloidosis
Patient Enrollment Qualifications
- Women and men 18 years of age or older
-
Histologically proven systemic anti-light chain amyloidosis confirmed by positive Congo red stain